INS and respiratory tract infectious disorder: We found that the risk of respiratory infections was lower when DPP-4 inhibitor therapy was used concomitantly with insulin, relative to the metformin + insulin combination regimen in male T2DM patients (adjusted OR 0.77; 95% CI 0.61–0.98, p = 0.04).